(MDT) Medtronic - Ratings and Ratios
Pacemaker, Defibrillator, Pump, Monitor, Stapler
Dividends
| Dividend Yield | 2.68% |
| Yield on Cost 5y | 2.87% |
| Yield CAGR 5y | 5.18% |
| Payout Consistency | 93.8% |
| Payout Ratio | 40.9% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 19.2% |
| Value at Risk 5%th | 29.6% |
| Relative Tail Risk | -6.19% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.01 |
| Alpha | 17.56 |
| CAGR/Max DD | 0.60 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.538 |
| Beta | 0.442 |
| Beta Downside | 0.611 |
| Drawdowns 3y | |
|---|---|
| Max DD | 22.77% |
| Mean DD | 6.03% |
| Median DD | 5.14% |
Description: MDT Medtronic September 25, 2025
Medtronic plc (NYSE: MDT) designs, manufactures and markets a broad suite of device-based medical therapies to hospitals, clinicians and patients across the United States, Ireland and the rest of the world. The company operates five primary segments: Cardiovascular, Neuroscience, Medical-Surgical, Diabetes, and a corporate-level function that supports global operations.
The **Cardiovascular Portfolio** supplies implantable pacemakers, implantable cardioverter-defibrillators (ICDs), cardiac resynchronization therapy devices, ablation tools, insertable cardiac monitors, TYRX drug-eluting technologies and remote-monitoring software. In FY 2023 the segment generated roughly $12 billion in revenue, accounting for about 40 % of total sales, and its growth is being driven by an expanding elderly population and increasing adoption of remote-monitoring platforms that improve post-implant outcomes.
The **Neuroscience Portfolio** covers spinal cord stimulation, deep-brain stimulation, implantable drug-infusion systems, nerve-ablation devices (Accurian) and related biologics. Demand is being fueled by a rise in chronic pain and neuro-degenerative disorders; the segment posted a 7 % year-over-year revenue increase in 2023, helped by the launch of next-generation high-frequency spinal stimulation systems that have shown superior pain-relief outcomes in recent clinical trials.
The **Medical-Surgical Portfolio** includes surgical staplers, vessel-sealing instruments, wound-closure tools, AI-driven video analytics, robotic-assisted platforms, hernia meshes, gynecologic devices, gastrointestinal diagnostics and airway-management products. Medtronic’s AI-powered surgical analytics platform saw a 35 % increase in active hospital sites in 2023, reflecting the broader surgical-technology market’s CAGR of roughly 9 % as hospitals seek efficiency gains and data-driven outcomes.
The **Diabetes Operating Unit** offers insulin pumps, continuous glucose monitoring (CGM) sensors, and the InPen smart-pen system. CGM shipments grew 18 % in 2023, propelled by expanding payer coverage and the shift toward hybrid closed-loop insulin delivery, positioning Medtronic as the second-largest CGM provider globally with an estimated 15 % market share.
Across the company, FY 2023 revenue reached $30.1 billion with an operating margin of 27 %, while R&D spending remained above $2.5 billion, underscoring Medtronic’s commitment to pipeline innovation amid a competitive landscape shaped by aging demographics, reimbursement pressure and supply-chain volatility. For a deeper dive into how these dynamics translate into valuation metrics, you may find ValueRay’s sector-specific analysis a useful next step.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (4.76b TTM) > 0 and > 6% of Revenue (6% = 2.09b TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA -0.43pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 31.46% (prev 31.04%; Δ 0.42pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 7.11b > Net Income 4.76b (YES >=105%, WARN >=100%) |
| Net Debt (26.30b) to EBITDA (9.27b) ratio: 2.84 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.85 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.29b) change vs 12m ago 0.05% (target <= -2.0% for YES) |
| Gross Margin 62.27% (prev 65.05%; Δ -2.78pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 38.25% (prev 36.65%; Δ 1.61pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 9.03 (EBITDA TTM 9.27b / Interest Expense TTM 710.0m) >= 6 (WARN >= 3) |
Altman Z'' 3.03
| (A) 0.12 = (Total Current Assets 23.81b - Total Current Liabilities 12.88b) / Total Assets 91.68b |
| (B) 0.34 = Retained Earnings (Balance) 31.48b / Total Assets 91.68b |
| (C) 0.07 = EBIT TTM 6.41b / Avg Total Assets 90.86b |
| (D) 0.63 = Book Value of Equity 27.19b / Total Liabilities 43.42b |
| Total Rating: 3.03 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 64.81
| 1. Piotroski 5.50pt |
| 2. FCF Yield 3.34% |
| 3. FCF Margin 14.98% |
| 4. Debt/Equity 0.59 |
| 5. Debt/Ebitda 2.84 |
| 6. ROIC - WACC (= 0.90)% |
| 7. RoE 9.83% |
| 8. Rev. Trend 76.35% |
| 9. EPS Trend 8.43% |
What is the price of MDT shares?
Over the past week, the price has changed by +4.08%, over one month by +12.98%, over three months by +15.41% and over the past year by +25.71%.
Is MDT a buy, sell or hold?
- Strong Buy: 12
- Buy: 5
- Hold: 13
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the MDT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 109.8 | 4.3% |
| Analysts Target Price | 109.8 | 4.3% |
| ValueRay Target Price | 116.3 | 10.4% |
MDT Fundamental Data Overview November 23, 2025
P/E Trailing = 27.4255
P/E Forward = 17.6367
P/S = 3.7953
P/B = 2.6607
P/EG = 2.4165
Beta = 0.739
Revenue TTM = 34.76b USD
EBIT TTM = 6.41b USD
EBITDA TTM = 9.27b USD
Long Term Debt = 25.59b USD (from longTermDebt, last fiscal year)
Short Term Debt = 2.87b USD (from shortTermDebt, last fiscal year)
Debt = 28.52b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 26.30b USD (from netDebt column, last fiscal year)
Enterprise Value = 156.10b USD (129.80b + Debt 28.52b - CCE 2.22b)
Interest Coverage Ratio = 9.03 (Ebit TTM 6.41b / Interest Expense TTM 710.0m)
FCF Yield = 3.34% (FCF TTM 5.21b / Enterprise Value 156.10b)
FCF Margin = 14.98% (FCF TTM 5.21b / Revenue TTM 34.76b)
Net Margin = 13.71% (Net Income TTM 4.76b / Revenue TTM 34.76b)
Gross Margin = 62.27% ((Revenue TTM 34.76b - Cost of Revenue TTM 13.11b) / Revenue TTM)
Gross Margin QoQ = 60.32% (prev 57.66%)
Tobins Q-Ratio = 1.70 (Enterprise Value 156.10b / Total Assets 91.68b)
Interest Expense / Debt = 0.63% (Interest Expense 181.0m / Debt 28.52b)
Taxrate = 13.47% (215.0m / 1.60b)
NOPAT = 5.54b (EBIT 6.41b * (1 - 13.47%))
Current Ratio = 1.85 (Total Current Assets 23.81b / Total Current Liabilities 12.88b)
Debt / Equity = 0.59 (Debt 28.52b / totalStockholderEquity, last fiscal year 48.02b)
Debt / EBITDA = 2.84 (Net Debt 26.30b / EBITDA 9.27b)
Debt / FCF = 5.05 (Net Debt 26.30b / FCF TTM 5.21b)
Total Stockholder Equity = 48.45b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.20% (Net Income 4.76b / Total Assets 91.68b)
RoE = 9.83% (Net Income TTM 4.76b / Total Stockholder Equity 48.45b)
RoCE = 8.65% (EBIT 6.41b / Capital Employed (Equity 48.45b + L.T.Debt 25.59b))
RoIC = 7.27% (NOPAT 5.54b / Invested Capital 76.29b)
WACC = 6.36% (E(129.80b)/V(158.32b) * Re(7.64%) + D(28.52b)/V(158.32b) * Rd(0.63%) * (1-Tc(0.13)))
Discount Rate = 7.64% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -1.68%
[DCF Debug] Terminal Value 78.53% ; FCFE base≈5.32b ; Y1≈5.41b ; Y5≈5.93b
Fair Price DCF = 81.58 (DCF Value 104.63b / Shares Outstanding 1.28b; 5y FCF grow 1.39% → 3.0% )
EPS Correlation: 8.43 | EPS CAGR: -0.20% | SUE: 2.62 | # QB: 4
Revenue Correlation: 76.35 | Revenue CAGR: 3.90% | SUE: 1.26 | # QB: 2
EPS next Quarter (2026-01-31): EPS=1.34 | Chg30d=-0.010 | Revisions Net=-1 | Analysts=27
EPS current Year (2026-04-30): EPS=5.64 | Chg30d=+0.016 | Revisions Net=-2 | Growth EPS=+2.7% | Growth Revenue=+7.5%
EPS next Year (2027-04-30): EPS=6.11 | Chg30d=+0.040 | Revisions Net=+1 | Growth EPS=+8.4% | Growth Revenue=+5.6%
Additional Sources for MDT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle